Evidence & Research
Science & Validation
Over 25 years of clinical evaluations, studies and research.
BEMER's aggregated clinical outcomes data spans 25+ years of clinical use across Europe and 40 countries. The data and information presented here mostly covers the foundational decade — 1999 to 2013 — across 15 medical specialties, 220 clinical facilities, and more than 3,000 documented patients. This is the base on which the Class IIa medical device classification and continued clinical development rest.
20+
Years of research
4M+
Users worldwide
43
Countries
Primary research partner
Institute for Microcirculation, Berlin
BEMER's core research was developed in collaboration with the Institute for Microcirculation (IfM) in Berlin — a specialist research institute focused on the physiology of small blood vessels and the mechanisms that govern blood flow through capillaries, arterioles, and venules.
The IfM's work established the scientific basis for BEMER's patented signal: a specific electromagnetic waveform calibrated to stimulate vasomotion — the rhythmic contraction and relaxation of small blood vessel walls that drives microcirculatory flow. This mechanism distinguishes BEMER from generic pulsed electromagnetic field (PEMF) devices, which do not target vasomotion specifically.
The collaboration produced peer-reviewed publications demonstrating measurable improvements in local microcirculatory blood flow following BEMER application — with independent studies recording increases of up to 29% after a single 8-minute session.
What the research shows
What the research shows, and its limits.
One sham-controlled trial we cite is a pilot study (Gyulai et al., 2015). 100 hospital inpatients, 50 with chronic low back pain and 50 with knee osteoarthritis, all followed the same physiotherapy programme. Half also used BEMER for 20 minutes a day for three weeks; half used an identical sham device that did nothing.
In the low back pain group, resting pain and fatigue were significantly lower with BEMER than with the sham device after three weeks. Disability scores (Oswestry) and quality of life did not change.
In the knee osteoarthritis group there was no difference at three weeks. Fatigue and vitality (SF-36) were significantly better with BEMER at three months.
It was a pilot study, so its results need confirming in larger trials.
Studies that did not show a difference
Auger et al. (2021) studied chronic low back pain in 40 adults across four arms. Pain fell in the BEMER-only arm, but there were no significant differences between groups. Biermann et al. (2021) studied 15 healthy volunteers and found no difference in skin blood flow between the treated and untreated limb. We list them because you should see both sides.
- Gyulai F, et al. Evid Based Complement Alternat Med. 2015;2015:245742. PMID 26078768.
- Auger K, et al. J Osteopath Med. 2021;121(6):561-569. doi:10.1515/jom-2020-0132.
- Biermann et al. Clin Hemorheol Microcirc. 2021. doi:10.3233/CH-209224.
Regulatory status
Class IIa medical device — European registration.
BEMER is registered as a Class IIa medical device under European CE marking requirements — the same regulatory tier as surgical instruments, infusion pumps, and diagnostic ultrasound equipment. Class IIa registration requires demonstrated clinical evidence of safety and efficacy under EU Medical Device Regulation (MDR 2017/745).
This is not a consumer wellness claim. BEMER is manufactured to medical device standards, with documented quality management and post-market surveillance — the same framework that applies to regulated medical equipment globally.
Clinical research areas
What the research covers.
Published and ongoing research on BEMER covers a wide range of clinical applications, with the strongest evidence base in conditions where microcirculatory dysfunction is a primary mechanism:
Diabetes & wound healing
Improved tissue oxygenation and healing in diabetic peripheral vascular disease
Cardiovascular conditions
Microcirculatory support in cardiac rehabilitation and heart failure management
Orthopaedic recovery
Accelerated bone healing, reduced post-surgical recovery time
Sports performance & recovery
Reduced muscle fatigue, faster lactate clearance, improved endurance
Neurological conditions
Microvascular support in stroke rehabilitation and neuropathy
Sleep & chronic fatigue
Improved parasympathetic tone and sleep quality in preliminary studies
Professional use
Used by professional sports teams and medical practitioners.
BEMER is used by professional and elite sports teams across Europe and internationally — including football clubs, cycling teams, and Olympic training programmes. The performance and recovery benefits documented in clinical research translate directly to athletic application: faster muscle recovery, reduced soreness, and better sleep between training sessions.
It is also used by physiotherapists, rehabilitation specialists, and integrative medicine practitioners in clinical settings across 43 countries — not as a replacement for medical treatment, but as an adjunct that addresses the microvascular dimension of recovery and chronic disease management.
Further reading
Published Studies
Four peer-reviewed publications in indexed medical journals — three randomised controlled trials (one a pilot study) and a statutory market monitoring study.
Research by Condition
Clinical outcomes across 30+ conditions indexed by evidence level — from the BEMER Medical Expert Center compendium, 1999–2013.
BEMER Research Overview
Published research and clinical findings
Key Clinical Studies
Peer-reviewed study summaries
Institute for Microcirculation, Berlin
The science behind the BEMER signal
The research referenced on this page reflects published and publicly available evidence on BEMER technology. Get Well Now is an independent BEMER SA Business Partner and does not conduct or fund research. BEMER therapy supports — but does not replace — medical treatment. Always consult your healthcare provider.